Table 1b.
Summary of Cohort (ii)
| Ang2 (N=121) | |
|---|---|
| Sex | |
| Female, n (%) | 72 (59.5) |
| Male, n (%) | 49 (40.5) |
| APOE ε4 carriership | |
| APOE-, n (%) | 60 (49.6) |
| APOE+, n (%) | 61 (50.4) |
| Age at LP | |
| Mean (SD) | 64.3 (6.79) |
| Amyloid status | |
| A-, n (%) | 57 (48.3) |
| A+, n (%) | 61 (51.7) |
| Tau status | |
| T-, n (%) | 74 (62.7) |
| T+, n (%) | 44 (37.3) |
| Clinical Diagnosis | |
| CU, n (%) | 84 (69.4) |
| MCI, n (%) | 20 (16.5) |
| Dementia, n (%) | 17 (14.0) |
Abbreviations: A+/− = Amyloid status, Ang2 = angiopoietin-2, APOE4 = apolipoprotein E ε4, CU = cognitively unimpaired, LP = lumbar puncture, MCI = mild cognitive impairment, sPDGFRβ = soluble platelet-derived growth factor receptor beta; T+/− = Tau status,
Note: Amyloid positivity was defined as CSF Aβ42/40 less than or equal to 0.046. Tau positivity was defined as CSF pTau181 concentration greater than 24.8 pg/mL. Clinical diagnosis was determined through a clinical consensus conference without reference to biomarker data.